Valuation: Orion Oyj

Market Cap 11.13B 13B 10.38B 9.53B 17.9B 1,244B 18.25B 123B 48.01B 623B 48.8B 47.74B 2,063B P/E 2026 *
19.7x
P/E 2027 * 16.8x
Enterprise Value 11.04B 12.89B 10.3B 9.45B 17.76B 1,234B 18.11B 122B 47.63B 618B 48.41B 47.35B 2,047B EV / Sales 2026 *
5.27x
EV / Sales 2027 * 4.56x
Free-Float
90.5%
Yield 2026 *
2.46%
Yield 2027 * 2.74%
1 day+1.03%
1 week+1.03%
Current month-2.96%
1 month+2.07%
3 months+11.93%
6 months+13.87%
Current year+24.68%
1 week 38.6
Extreme 38.6
39.4
1 month 38.2
Extreme 38.2
41
Current year 31.6
Extreme 31.6
41
1 year 28.6
Extreme 28.6
41
3 years 15.2
Extreme 15.2
41
5 years 15.2
Extreme 15.2
41
10 years 15.2
Extreme 15.2
41
Manager TitleAgeSince
Chief Executive Officer 59 2022-10-31
Director of Finance/CFO 50 2024-04-30
Chief Operating Officer 46 2021-12-31
Director TitleAgeSince
Director/Board Member 63 2017-03-21
Director/Board Member 65 2017-03-21
Director/Board Member 66 2020-05-05
Change 5-day change 1-year change 3-year change Capi.($)
+1.03%+1.03% - - 12.99B
-2.81%+2.93%+76.40%+127.73% 1,141B
-2.21%+2.02%+49.50%+55.01% 659B
-1.56%+4.39%+25.19%+74.39% 470B
+1.20%+2.62%+41.69%+45.78% 366B
-0.61%+2.10%+23.43%+41.34% 302B
+0.32%+3.25%+0.94%+13.42% 254B
-1.95%+3.80%+46.31%+65.66% 239B
-1.10%-0.70%-14.31%-52.66% 207B
-2.82%+3.84%+20.81%+89.04% 183B
Average -1.05%+2.87%+30.00%+51.08% 424.55B
Weighted average by Cap. -1.63%+3.12%+43.48%+70.86%

Financials

2026 *2027 *
Net sales 2.1B 2.45B 1.96B 1.79B 3.37B 234B 3.44B 23.2B 9.05B 117B 9.19B 8.99B 389B 2.37B 2.76B 2.21B 2.03B 3.81B 264B 3.88B 26.2B 10.21B 133B 10.38B 10.15B 439B
Net income 564M 659M 527M 483M 908M 63.08B 926M 6.25B 2.44B 31.61B 2.48B 2.42B 105B 660M 771M 616M 565M 1.06B 73.8B 1.08B 7.31B 2.85B 36.99B 2.9B 2.83B 122B
Net Debt -89.76M -105M -83.75M -76.85M -144M -10.03B -147M -994M -387M -5.03B -394M -385M -16.64B -333M -389M -311M -285M -536M -37.21B -546M -3.69B -1.44B -18.65B -1.46B -1.43B -61.74B
Logo Orion Oyj
Orion Oyj is Finland's leading pharmaceutical group. Net sales break down by family products and services as follows: - innovative medicines (43%): for the treatment of cancer and pain management; - generic, OTC and biosimilar drugs (29.3%); - branded prescription products (16.6%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments; - veterinary products (7.5%); - pharmaceutical ingredients and outsourcing services (3.6%). Net sales break down primarily by source of revenue between sales of products (67.2%) and royalties (23.1%). Net sales are distributed geographically as follows: Finland (19.3%), Scandinavia (10%), Europe (28.1%), North America (25.5%) and other (17.1%).
Employees
4,000
Date Price Change
26-08-20 €39.40 +1.03%
26-08-19 €39.00 +1.04%
26-08-18 €38.60 0.00%
26-08-17 €38.60 -3.02%
26-08-14 €39.80 +2.05%
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
79.05EUR
Average target price
76.67EUR
Spread / Average Target
-3.01%

Quarterly revenue - Rate of surprise